Waverley Pharma (TSXV:WAVE) EV-to-EBIT : -2.13 (As of May. 21, 2024)

View and export this data going back to 2017. Start your Free Trial

What is Waverley Pharma EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Waverley Pharma's Enterprise Value is C$2.63 Mil. Waverley Pharma's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was C$-1.23 Mil. Therefore, Waverley Pharma's EV-to-EBIT for today is -2.13.

The historical rank and industry rank for Waverley Pharma's EV-to-EBIT or its related term are showing as below:

TSXV:WAVE' s EV-to-EBIT Range Over the Past 10 Years
Min: -13.13 Med: -4.1 Max: -0.31
Current: -2.13

During the past 8 years, the highest EV-to-EBIT of Waverley Pharma was -0.31. The lowest was -13.13. And the median was -4.10.

TSXV:WAVE's EV-to-EBIT is ranked worse than
100% of 427 companies
in the Biotechnology industry
Industry Median: 10.09 vs TSXV:WAVE: -2.13

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Waverley Pharma's Enterprise Value for the quarter that ended in Dec. 2023 was C$2.90 Mil. Waverley Pharma's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was C$-1.23 Mil. Waverley Pharma's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was -42.50%.

Waverley Pharma EV-to-EBIT Historical Data

The historical data trend for Waverley Pharma's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Waverley Pharma EV-to-EBIT Chart

Waverley Pharma Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EV-to-EBIT

Get a 7-Day Free Trial

-2.77

-8.56

-5.62

-3.43

-2.35

Waverley Pharma Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
EV-to-EBIT	Get a 7-Day Free Trial															-3.43	-4.25	-3.50	-2.39	-2.35

Competitive Comparison of Waverley Pharma's EV-to-EBIT

For the Biotechnology subindustry, Waverley Pharma's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Waverley Pharma's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Waverley Pharma's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Waverley Pharma's EV-to-EBIT falls into.

Waverley Pharma EV-to-EBIT Calculation

Waverley Pharma's EV-to-EBIT for today is calculated as:

EV-to-EBIT	=	Enterprise Value (Today)	/	EBIT (TTM)
	=	2.629	/	-1.232
	=	-2.13

Waverley Pharma's current Enterprise Value is C$2.63 Mil.
Waverley Pharma's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was C$-1.23 Mil.

Waverley Pharma (TSXV:WAVE) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Waverley Pharma's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Dec. 2023 )	=	EBIT	/	Enterprise Value (Q: Dec. 2023 )
	=	-1.232	/	2.899
	=	-42.50 %

Waverley Pharma's Enterprise Value for the quarter that ended in Dec. 2023 was C$2.90 Mil.
Waverley Pharma's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was C$-1.23 Mil.

Waverley Pharma EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Waverley Pharma's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Waverley Pharma (TSXV:WAVE) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Waverley Pharma Inc (TSXV:WAVE) » Definitions » EV-to-EBIT

Comparable Companies

Traded in Other Exchanges

5GZ:Germany

Address

1250 Waverley Street, Suite 4, Winnipeg, MB, CAN, R3T 6C6

Website

https://www.waverleypharma.com

Waverley Pharma Inc is a biopharmaceutical company. It is engaged in the research, development, and commercialization of human therapeutics that focuses on oncology. The company products pipeline includes Capecitabine and Temozolomide, among others.

Executives

Albert David Friesen

10% Security Holder, Director, Senior Officer